Clinical importance of the antibiotic regimen in transrectal ultrasound-guided biopsy: quinolone versus cephalosporin by Jung Keun Lee et al.
RESEARCH ARTICLE Open Access
Clinical importance of the antibiotic
regimen in transrectal ultrasound-guided
biopsy: quinolone versus cephalosporin
Jung Keun Lee1,2, Sangchul Lee1,2*, Sung Kyu Hong1,2, Seok-Soo Byun1,2 and Sang Eun Lee1,2
Abstract
Background: Quinolone is recommended as an antimicrobial prophylaxis to prevent infectious complication after
transrectal ultrasound-guided biopsy, but the increased appearance of quinolone-resistant organism has raised
concerns about the efficacy of quinolone. The current study was performed to evaluate various clinical factors
including antimicrobial regimens associated with infectious complication after transrectal ultrasound-guided
prostate biopsy.
Methods: The medical records of 5215 patients who underwent a multicore transrectal ultrasound-guided prostate
biopsy between May 2003 and January 2013 at our institution were reviewed. We analyzed clinical variables
including prostate-specific antigen, International Prostate Symptom Score, antimicrobial regimen, prostate size, and
number of biopsy cores. Univariate and multivariate logistic regression analyses of infection-related hospitalization
after prostate biopsy were performed.
Results: The mean age and median prostate-specific antigen of the entire cohort were 66 years and 6.4 ng/ml,
respectively. Twenty-eight (0.54 %) patients developed an infectious complication after prostate biopsy that
required hospitalization. Patients who received prophylactic quinolone showed a higher infectious hospitalization
rate than patients who received prophylactic third-generation cephalosporin (1.5 vs. 0.3 %; p < 0.001). Multivariate
logistic regression analysis demonstrated that the International Prostate Symptom Score (odds ratio = 3.18, 95 %
confidence interval 1.24–8.13, p = 0.016) and the use of third-generation cephalosporin (odds ratio = 0.21, 95 %
confidence interval 0.10–0.44, p < 0.001) were independent predictors of infection-related hospitalization after
prostate biopsy.
Conclusion: With the emergence of quinolone-resistant microorganisms, third-generation cephalosporin may
effectively reduce the risk of infectious complications after transrectal ultrasound-guided prostate biopsy. Severe
lower urinary tract symptoms may also be an independent risk factor for infection-related hospitalization after
transrectal ultrasound-guided prostate biopsy.
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Background
Transrectal ultrasound-guided prostate biopsy (TRUS-
PBx) is the standard procedure for diagnosing prostate
cancer, and several million TRUS-PBx procedures are
performed annually worldwide [1]. However, one of the
most serious complications associated with TRUS-PBx is
infection such as urosepsis which can be potentially
fatal. The hospital admission rate due to infectious
complications after TRUS-PBx has been reported as
0.8–3.6 % of patients [2–4]. Although appropriate anti-
microbial prophylaxis is generally administered, an in-
creased trend in infection-related hospitalization after
TRUS-PBx has recently been reported [5–7]. Potential
risk factors for infectious complications after TRUS-PBx
included a high comorbidity index, uncontrolled dia-
betes mellitus, large prostate, untreated bacteriuria, an
indwelling urinary catheter, bladder stones, and a recent
history of urinary infection such as bacterial prostatitis
[8, 9]. The most important clinical risk factor among
many is the presence of antibiotic-resistant pathogens in
the rectal flora [6, 8, 9].
Antibiotic regimens play a key role in the management
of TRUS-PBx and oral fluoroquinolones are used exten-
sively for standard antibiotic prophylaxis [10, 11]. How-
ever, fluoroquinolone-resistant species are increasing, so
the frequency of infectious complications with these
antibiotic-resistant organisms is likely to increase [12–14].
Various antimicrobial prophylactic regimens have been
proposed previously to decrease the infectious complica-
tion rate after TRUS-PBx [4, 15].
In the present study, we investigated the various clinico-
pathological factors associated with infectious complica-
tions after TRUS-PBx. Our country has an extended
national health insurance policy that covers the expenses
of an inpatient stay for the entire population [16], so most
patients in our facility underwent TRUS-PBx as inpatients.
Consequently, we had a unique opportunity to analyze the
incidence of infectious complications in patients who were
managed by physicians following TRUS-PBx.
Methods
We retrospectively analyzed the electronic medical re-
cords of 5376 patients who underwent a multicore TRUS-
PBx after admission to our institution between May 2003
and January 2013. Clinical characteristics including age,
body mass index, diabetes mellitus, prostate-specific anti-
gen (PSA), International Prostate Symptom Score (IPSS),
the antimicrobial regimen, prostate size, number of biop-
sies, and TRUS-PBx complications were evaluated. We
excluded the patients who were administered other pro-
phylactics (n = 77), and patients with insufficient medical
data (n = 84). Finally, clinicopathological data for 5215 pa-
tients were analyzed.
Most TRUS-PBx within our institute were performed
in an inpatient setting. The decision to admit a patient
was made on the basis of concern of patient or the pref-
erence of the physician. Patients provided written in-
formed consent, and underwent a single glycerin enema
on the day of the biopsy. Most urine cultures were per-
formed for 1–3 weeks before TRUS-PBx. If the urine
culture showed clinically significant growth of bacteria,
antibiotics based on the urine culture were prescribed
and TRUS-PBx was delayed until the patients had recov-
ered from infection. If no significant growth of bacteria
was seen in the urine culture, physician-preferred
prophylactic antibiotics were administered intravenously
once before biopsy. Third generation cephalosporin was
generally the preferred antibiotic in recent years. Be-
tween 2008 and 2013, 168 (6 %) patients were given
quinolone before biopsy, and 2699 patients (94 %) were
given third-generation cephalosporin as prophylactic an-
tibiotics. The quinolone group received a single dose of
400 mg ciprofloxacin or 250 mg leveofloxacin. Third-
generation cephalosporin groups received a single dose
of 1 g flomoxef, 1 g ceftriaxone, or 1 g ceftizoxime. All
patients underwent prophylactic antibiotics with the
dose adjusted to renal and hepatic function. Thereafter,
all patients received oral antibiotics for 2 days after
TRUS-PBx. Two experienced radiologists performed
TRUS-PBx, which is a routine, standard multicore bi-
opsy that is performed using local anesthesia. In the in-
patient setting, patients stayed in the hospital for 1 day
or until the absence of complications such as rectal
bleeding or gross hematuria was confirmed. Patients
who underwent TRUS-PBx were instructed to go to an
emergency room or urologic clinic if they developed a
high fever, severe bleeding, or severe lower urinary tract
symptoms including urinary retention. All patients were
followed up as at outpatients within 2 weeks. Physicians
recorded the results of TRUS-PBx and evaluated the
complications at the follow-up.
Infection-related hospitalization after TRUS-PBx was
defined as a new admission to the hospital or a delaying
discharge due to a systemic inflammatory syndrome
such as a fever of 37.8 °C (100 °F) or higher within 2
weeks of TRUS-PBx regardless of significant growth of
bacteria in a blood culture. Initiating antibiotic therapy
was deferred until blood cultures were obtained in the
case of infection-related hospitalization after TRUS-PBx.
Blood cultures were available in all patients with infec-
tious complications. Although no standard guidelines
exist for management of infectious complications after
TRUS-PBx, empirical patient-specific antimicrobial ther-
apy was administered, followed by culture-driven anti-
microbial therapy if TRUS-PBx-related sepsis occurred.
The primary clinical data were treated as categorical
or continuous variables and screened for the entire
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group of patients. Univariate and multivariate logistic re-
gression analyses of infection-related hospitalization
after TRUS-PBx were performed. All p values were two-
sided, and values <0.05 were considered to be statisti-
cally significant. Adjusted odds ratios (OR) and their
95 % confidence intervals (CI) were calculated using mul-
tiple logistic regression analyses. All data analyses were
performed using the Statistical Package for the Social
Sciences® 18.0 software (SPSS Inc., Chicago, IL, USA).
This study was conducted in compliance with the
Helsinki Declaration and approved by our local ethics com-
mittee. The reference number of Seoul National University
Bundang Hospital Institutional Review Board is B-1407/
260-111. The ethics committee did not require informed
patient consent because the study was retrospective. Data
from medical records were analyzed after anonymization.
Results
Clinicopathological characteristics of the 5215 TRUS-
PBx patients included in the final analysis are shown
Table 1. The mean age and median PSA of the entire co-
hort were 64.7 ± 9.3 years and 6.5 ng/ml (interquartile
range, 4.3–10.6 ng/ml), respectively. Of these patients,
19 % were included in the quinolone group and 81 % in
the third-generation cephalosporin group. Twenty-eight
(0.54 %) patients developed an infectious complication
that required hospitalization after TRUS-PBx (Table 1).
Univariate and multivariate logistic regression analyses of
infection-related hospitalization after TRUS-PBx are shown
in Table 2. Univariate analyses indicated that a prophylactic
antibiotics regimen based on third-generation cephalo-
sporin (OR = 0.20, 95 % CI 0.10–0.42, p < 0.001) and severe
IPSS (OR = 3.37, 95 % CI 1.32–8.60, p = 0.011) were inde-
pendent predictors of infection-related hospitalization after
TRUS-PBx (Table 2). Multivariate analysis of 4932 patients
indicated that third-generation cephalosporin (OR = 0.21,
95 % CI 0.10–0.44, p < 0.001) and severe IPSS (OR = 3.18,
95 % CI 1.24–8.13, p = 0.016) were also independent
predictors of infection-related hospitalization after
TRUS-PBx (Table 2).
Ten of the 15 patients with infectious complications
who received prophylactic quinolone showed quinolone-
resistant Escherichia coli in a blood culture, and three of
this subgroup developed septic shock, that resulted in
one death (Table 3). A lower rate of isolated bacteria,
which was resistant to prophylactic antibiotics was ob-
served in patients who were admitted after receiving
prophylactic third-generation cephalosporin versus quin-
olone (3/13 [23.1 %] vs. 10/15 [66.7 %], p = 0.021). Inter-
estingly, none of the patients who received prophylactic
third-generation cephalosporin developed septic shock
or died (Table 3). Eleven of 28 patients hospitalized due
to high fever after TRUS-PBx showed no significant
growth of bacteria in culture. However, the fever in these
patients was controlled with conservative management
including adequate administration of antibiotics.
Discussion
Until innovative new technology can replace the TRUS-
PBx in the future, this procedure will be performed several
million times every year worldwide to diagnose prostate
cancer. Several prevention strategies to reduce serious
infectious complications after TRUS-PBx have been
attempted to improve the safety of patients undergoing this
procedure. Among the strategies, antibiotic prophylaxis
can play an important key role in prevention of infection
after TRUS-PBx. Current guidelines recommended the use
of fluoroquinolones or cephalosporin (first generation, sec-
ond generation, or third generation) before prostate biopsy
[17]. Alternative antimicrobial regimens such as aminogly-
cosides plus metronidazole or clindamycin have been rec-
ommended [17]. In many studies, fluoroquinolones were
used to examine empirical antimicrobial prophylaxis before
prostate biopsy. In addition, fluoroquinolone-based anti-
microbial prophylaxis is still used worldwide for standard
antibiotic prophylaxis [18].
Table 1 Comparison of clinicopathological features among
men who underwent a contemporary multicore prostate biopsy
Variable Entire cohort
Number of patients 5215
Median age (years)(IQR) 66 (60–71)
Mean BMI (kg/m2) 24.3 ± 2.7
Diabetes mellitus (%) 742 (14.2)
Median PSA (ng/mL)(IQR) 6.4 (4.3–10.5)










Third-generation cephalosporin 4225 (81.0)
Number of biopsy cores (%)
≤ 12 3470 (66.5)
≥ 13 1745 (33.5)




Admission for infectious complications (%) 28 (0.54)
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However, an increasing rate of infectious complica-
tions after TRUS-PBx due to the emergence of
fluoroquinolone-resistant bacteria has recently been re-
ported [12–14]. Adibi et al. showed that the addition of
one dose of intramuscular gentamicin with ciprofloxacin
reduced the rate of re-hospitalization due to infectious
complications after prostate biopsy from 3.8 to 0.6 % [4].
Gianna et al. reported that a combination of orally
administered quinolone and periprostatic injection of ceph-
alosporin controls infection caused by fluoroquinolone-
resistant E.coli [19]. The rates of rehospitalization after
TRUS-PBx were 5.7 and 0 % in the conventional quinolone
group and the combination group, respectively [19]. Bartus
et al. reported that adding amikacin to fluoroquinolone-
based antimicrobial prophylaxis confers a significant benefit
in preventing infections after TRUS-guided biopsy [20]. In
contrast, Hori et al. reported that ciprofloxacin provides su-
perior prophylaxis compared to co-amoxiclav in men
undergoing TRUS-PBx [21]. Although eight men (7.3 %) in
the co-amoxiclav group developed sepsis, only two men in
the ciprofloxacin group (1.7 %) developed sepsis after
TRUS-PBx [21].
The prevalence of antimicrobial-resistant E.coli has
changed in Korea, Lee et al. recently reported on data
from the Korean antimicrobial resistance monitoring
system between 2008 and 2009 that indicated E.coli iso-
lates from cystitis patients had 75 % susceptibility to
quinolone and 95 % susceptibility to third-generation
cephalosporin [22]. Resistant E.coli rates also have also
increased in other Asian countries [23]. Our study shows
that use of third-generation cephalosporin before TRUS-
PBx resulted in a significant decrease in infection-related
hospitalization after TRUS-PBx. The pathogenesis of in-
fectious complications after TRUS-PBx can be explained
by the invasion of bacteria from the gastrointestinal
tract, and cephalosporins are recommended as a prophy-
lactic antibiotic in colorectal surgery [24]. The most ap-
propriate regimen during TRUS-PBx is controversial.
Our results showed that a regimen of prophylactic third-
generation cephalosporin has a significant advantage in
Table 2 Univariate and multivariate analyses of infection-related hospitalization after prostate biopsy
Variable Univariate Multivariatea
OR (95 % CI) p value OR (95 % CI) p value
Age
< 70 1.0
≥ 70 0.83 (0.38–1.89) 0.655
BMI 0.99 (0.86–1.13) 0.825
Diabetes mellitus 0.72 (0.22–2.40) 0.595
Prostate volume 1.00 (0.98–1.02) 0.941
IPSS
Mild 1.0 1.0
Moderate 0.36 (0.36–2.60) 0.947 0.94 (0.35–2.52) 0.936
Severe 3.37 (1.32–8.60) 0.011 3.18 (1.24–8.13) 0.016
Year of prostate biopsy
2003–2007 1.0
2008–2013 0.71 (0.34–1.49) 0.364
Number of biopsy cores taken
≤ 12 1.0
≥ 13 1.29 (0.60–2.76) 0.514
Antibiotic prophylaxis
Quinolone 1.0 1.0
third-generation Cephalosporin 0.20 (0.10–0.42) <0.001 0.21 (0.10–0.44) <0.001
aLogistic regression analysis used to evaluate 5215 patients
Table 3 Clinical features of patients hospitalized due to
infectious complications after prostate biopsy
Variable Quinolone Third generation
cephalosporin
Number of patients (%) 15 13
Isolated bacteria (%) 73.3 (11/15) 46.2 (6/13)
Escherichia coli 10/11 1/6
Enterococcus 1/11 3/6
Coagulase-negative staphylococcus 0/11 1/6
Klebsiella pneumoniae 0/11 1/6
Septic shock (%) 20 (3/15) 0
Mortality (%) 6.7 (1/15) 0
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the context of preventing rehospitalization due to infec-
tious complications after TRUS-PBx in an era of the
emergence of quinolone-resistant microorganisms.
Interestingly, our data showed that severe symptoms
on the IPSS questionnaire were significantly associated
with hospitalization after TRUS-PBx. As lower urinary
tract symptoms may partially indicate inflammation of
the prostate and periprostatic tissue, TRUS-PBx could
aggravate the inflammatory status of the prostate and re-
sult in a systemic inflammatory syndrome with high
fever after prostate biopsy. Moreover, antibiotic-resistant
bacteria increase following pre-administration of medi-
cation for prostatitis [12]. Mosharafa et al. reported that
prior fluoroquinolone intake is a significant risk factor
for acute prostatitis after TRUS-guided biopsy [14]. Add-
itionally, the results of increased infection could be ex-
plained by bladder emptying which is known to be a
very important factor in preventing urinary tract infec-
tion. High IPSS scores would be associated with inad-
equate bladder emptying, which could cause bacterial
growth. In light of these findings, we consider the IPSS
score in our current TRUS-PBx protocol, and recom-
mend more stringent protocols for prophylaxis in men
high IPSS scores.
Some controversy remains regarding the association
between infection-related complications after prostate
biopsy and procedure-related risk factors such as num-
ber of biopsy cores [6–8, 25]. Our study demonstrated
that the number of biopsy cores was not associated with
infection-related hospitalization after TRUS-PBx.
In the present study, we performed TRUS-PBx in an
inpatient setting and we prescribed long-term use of an-
tibiotics. However, the duration of administration of
prophylactic antimicrobials remains controversial issues,
even though a recent meta-analysis reported that long-
term use of antibiotics (3 days) is not superior to short-
course prophylactic (1 day) use in terms of symptomatic
infections after prostate biopsy [18],. Furthermore, med-
ical services depend not only on clinical guidelines but
also patient preference or health insurance policies.
Moreover, we thought that the reason for a low level of
infectious hospitalization (0.54 %) may be due to our
prophylactic management. Adibi et al. also demonstrated
that a significant hospitalization for post-biopsy infec-
tious complications from 3.8 % (11/290) to 0.6 % (2/310)
after addition of gentamicin to quinolone [4].
The limitations of our study include its retrospective
nature and the fact that the data were obtained from a
single institution. Only 28 events of infection-related
hospitalization after TRUS-PBx were observed in this
cohort. This low number of events could compromise
the accuracy of the model prediction. In addition, we
could not assess specific information about the recent
patient history of prior antibiotic use or urinary tract
infection before TRUS-PBx. Also, because we studied
data from a primarily inpatient only cohort, (only 5 % of
patients underwent TRUS-PBx in the outpatient setting
at our institute during the study period), our findings
may not be applicable to patients in other setting under-
going TRUS-PBx. We focused on the effect of prophy-
lactic antibiotics on infectious complications, thus we
did not enroll out patients to avoid confounding. Fur-
thermore, there may be an issue regarding the increasing
risk of third generation cephalosporin resistance. Over-
all, we believe study so our findings warrant additional
investigation using a randomized controlled trial.
Conclusions
With the emergence of quinolone-resistant microorgan-
isms, third-generation cephalosporin may effectively re-
duce the risk of infectious complications after TRUS-PBx.
Severe lower urinary tract symptoms may also be an inde-
pendent risk factor for infection-related hospitalization
after TRUS-PBx. A large-scale, multicenter, prospective
study is needed to fully evaluate the regimen of prophylac-
tic antimicrobials in TRUS-PBx.
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